This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
30 Sep 2011

Takeda Submits New Drug Application for TAK-085

Takeda has submitted a New Drug Application in Japan for TAK-085 for the treatment of hyperlipidemia.

Pronova BioPharma and Takeda Pharmaceutical announced Thursday that Takeda submitted a New Drug Application (NDA) to the Japanese regulators for TAK-085 (omega-3-acid ethyl esters 90) for the treatment of hyperlipidemia.

 

This submission is based on the results of the phase 3 clinical trial to evaluate the efficacy and safety of TAK-085 for patients with hypertriglyceridemia [baseline triglyceride level, 150 to 750 mg/dL], in comparison with an active comparator EPA (eicosapentaenoic acid) product already marketed in Japan.

 

TAK-085, discovered by Pronova, is the omega 3-derived prescription drug containing highly concentrated and purified EPA-E (eicosapentaenoic acid ethyl ester) and DHA-E (docosahexaenoic acid). It is already on the market in 56 countries including the

Related News